Applied NeuroSolutions Announces US Patent Issued Covering Unique Gene Potentially Involved in Onset of Alzheimer’s Disease
Complete the form below to unlock access to ALL audio articles.
Applied NeuroSolutions, Inc. has announced a US Patent, entitled “Novel Saitohin Gene and Uses of Same” (the “Patent”) was issued to Albert Einstein College of Medicine (AECOM).
APNS has exclusive rights to this patent for use in Alzheimer’s disease and other neurodegenerative diseases, through its licensing agreements with AECOM. The inventors on the Patent are Dr. Peter Davies, APNS’s founding scientist, and Dr. Chris Conrad.
Dr. Davies, a thought leader in AD research, has focused on the role of the protein tau in the development of neurofibrillary tangles, a hallmark pathology of AD. In conjunction with APNS, Dr. Davies has also been working on applications of these proteins directed toward creating therapeutics to treat, and diagnostics to detect, Alzheimer’s disease.
The novel Saitohin (STH) gene, covered in the newly granted patent, is a gene that is nested within the tau gene that in turn creates the tau protein. Initial genetic studies of the Saithoin gene indicate it could prove valuable in the study of risk factors in AD as well as other neurodegenerative disorders that exhibit tau based pathologies.
“This patent is a welcome addition to our existing IP estate and further strengthens our tau- based approach to treating and detecting AD,” said Ellen R. Hoffing, President and CEO of Applied NeuroSolutions.
"This composition of matter patent provides APNS with the opportunity to combine our unique knowledge of the role of the tau gene and its connection with the STH gene as we focus on the development and commercialization of both diagnostics and therapeutics for Alzheimer’s patients.”
Dr. Peter Davies added, “The Saitohin gene and the two different proteins it produces may be involved in early events in the development of Alzheimer’s disease and/or other tau related disorders. The exploration of the relationship of STH to tau pathology will add significantly to APNS’s already exciting programs of developing diagnostics for AD as well as the development of therapeutics through its collaboration with Eli Lilly and Company (NYSE:LLY).”
